Low Dose Dexmedetomidine Versus Ketamine in Multiple Fracture Ribs

Launched by ASSIUT UNIVERSITY · Jun 10, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating how two different medications, low-dose dexmedetomidine and ketamine, affect patients with multiple fractured ribs who are receiving conservative treatment, like chest strappings. The main focus is to see which medication better helps with pain management, improves diaphragm function, and reduces inflammation.

To participate in this study, you need to be an adult between 18 and 65 years old with at least three broken ribs due to an injury, and you should be experiencing significant pain despite standard treatments. Participants will undergo thorough assessments and will be monitored to see how well each medication works. It’s important to note that certain health conditions may prevent someone from joining the trial, such as serious head injuries or other major trauma. If you or a loved one is dealing with multiple rib fractures and is interested in this study, it could be a valuable opportunity to explore new pain relief options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (age 18-65 years) of American Society of Anaesthesiologists (ASA) physical status I-II
• • Traumatic multiple fracture ribs 3 ribs or more, who will be subjected to thorough assessments including chest 3D-CT
• • Undergoing conservative treatment (chest strappings)
• • Intractable pain with visual analogue scale (VAS) over 6 after traditional therapies
• • Glasgow Coma Scale (GCS) ≥ 13.
• Exclusion Criteria:
• • Multiple traumas to body parts other than chest with an abbreviated injury scale over 3
• • Serious head trauma with a Glasgow coma scale lower than 13
• • Mechanically ventilated patients
• • Massive hemothorax
• • Injury to the trachea or bronchus with requirement for immediate surgery
• • Dementia
• • Use of corticosteroids during ICU stay
• • Sepsis
• • Continued use of neuromuscular blocking agents and aminoglycosides antibiotic use as they are known risk factors for ICU-acquired weakness and any known hypersensitivity
• • Contraindication to the study drugs.